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NEXT GEN CAR T CELLS
Michael C. Jensen, MD
Janet & Jim Sinegal Endowed Professor of Pediatrics, Adjunct Professor of Bioengineering, University of
Washington School of Medicine
Director, Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute
Joint Member, Program in Immunology, Fred Hutchinson Cancer Research Center
michael.jensen@seattlechildrens.org

Recent conceptual as well as technological advances in the areas of molecular immunology, gene
transfer, and cell processing have fostered increasingly sophisticated translational applications of
adoptive T cell therapy for oncologic disease employing genetically-modified T-lymphocytes. My
laboratory’s work focuses on T-cell genetic modification for re-directing antigen specificity to tumors
utilizing recent advances not only in the composition and specificity of receptor antigen recognition
domains, but also the evolution of multifunctional cytoplasmic signaling domains developed for these
chimeric antigen receptors (CARs) that provide dual activation and co-stimulatory signaling. My group is
also investigating the context of adoptive transfer with respect to the conditioning of the recipient for
enhanced T-cell engraftment and expansion, the grafting of CARs on to central memory T-cells having
endogenous TCR specificities for viral epitopes to which the host has robust immunity, and, the provision
tumor microenvironment survival capabilities. The increasingly broad array of genetic manipulations
including not only transgene insertion, but targeted gene knock out using engineered targeted nucleases
such as TALEN’s and ZFN, as well as expression regulatory constructs provides for the creation of
synthetic biology of orthogonal immune responses based on gene modified T cell adoptive transfer. The
next decade of advances in this arena will depend on iterative bench-to-bedside back-to-the-bench
translational studies capable of sustaining the evolution of these technologies in the context of clinical
parameters relevant to the pediatric oncology patient population.

